102 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
The potential for a therapeutic strategy that not only achieves significant weight loss but also preserves crucial muscle mass and bone health would be a major advancement in obesity management. Current weight loss ap…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
This case highlights the critical importance of vigilant monitoring of thyroid function in post-thyroidectomy patients initiating tirzepatide or similar incretin-based medications. The significant weight loss and pote…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
The findings from this study are highly significant for patients managing type 2 diabetes and obesity with Tirzepatide. Knowing that injection site (upper arm, thigh, or abdomen) does not significantly impact drug abs…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
The study, currently underway, aims to demonstrate the significant efficacy of Tirzepatide in reducing liver fat deposition in patients with Type 2 Diabetes and NAFLD with advanced fibrosis. Based on Tirzepatide's wel…
This case report is highly significant as it identifies a potential rare but serious adverse event associated with tirzepatide use in a patient population not traditionally considered at high risk for ketoacidosis. It…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…